Pfizer’s Covid-19 vaccine proves 90% effective in latest trials
Pfizer, Biontech coronavirus vaccine could be available by end of year: Dr. Siegel
Fox News Medical Contributor Dr. Marc Siegel on the announcement of positive data from Pfizer and Biontech’s coronavirus vaccine and the politicization of wearing masks.
A vaccine developed by Pfizer Inc. and partner BioNTech SE proved better than expected at protecting people from COVID-19 in a pivotal study, a milestone in the hunt for shots that can stop the global pandemic.
Continue Reading Below
The vaccine proved to be more than 90% effective in the first 94 subjects who were infected by the new coronavirus and developed at least one symptom, the companies said Monday.
The positive, though incomplete, results bring the vaccine a big step closer to getting cleared for widespread use.
Stocks in this Article
PFIZER MAY APPLY FOR EMERGENCY USE OF COVID-19 VACCINE BY LATE NOVEMBER
Pfizer said it is on track to ask health regulators for permission to sell the shot before the end of this month, if pending data indicate the vaccine is safe.
The timetable suggests the vaccine could go into distribution this month or next, though U.S. health regulators have indicated they will take some time to conduct their review.
“Hopefully now we can move on and get this vaccine out there and make sure it’s doing what it’s supposed to do and stop” the virus, said Kathrin Jansen, Pfizer’s head of vaccine research and development, in an interview.
The findings came too early for researchers to assess the safety of the vaccine, which the U.S. Food and Drug Administration says must include two months of monitoring at least half the study’s subjects for side effects.
PFIZER, BIONTECH BEGIN CORONAVIRUS VACCINE TRIALS IN KIDS, PUBLISH EARLY-STAGE DATA
Pfizer said it remains on track to collect at least two months of safety data during the third week of November and could file for an emergency authorization shortly thereafter.
So far, no serious safety issues have arisen in the study, the companies said. The study has enrolled nearly 44,000 subjects in the U.S. and other countries.
It is unclear how long the protection the vaccine appears to provide lasts, since researchers haven’t been studying volunteers for very long.